|
Charterhouse Capital Partners
Charterhouse Capital Partners is a London based private equity investment firm focused on investing in European mid-market companies valued between €200m and €1.5bn.[1] The company targets investments across the services, healthcare, specialised industrials and consumer sectors.[2] HistoryFounded in 1934,[3] Charterhouse Capital Partners is one of Europe’s oldest private equity firms.[4] The firm's predecessors, then a division of Charterhouse Bank, began raising third party equity in 1976.[3] In June 2001, the firm's management completed a management buyout from HSBC to become an independent investment firm.[5] Notable investment activityIn 2009, Charterhouse acquired Wood Mackenzie, selling its stake to Hellman & Friedman in 2012.[6] In 2010, the company acquired Deb Group, a skincare product group, and sold its stake in 2015 to SC Johnson, reportedly earning a return of over 2.5x.[7] In 2010, they acquired Card Factory, exiting its stake in 2015.[8] In 2011, the company acquired ERM, and in 2015, sold its stake to Omers in a deal valued at $1.7 billion.[9] In 2011, they acquired Webhelp, selling the company to KKR in 2015.[10] In 2013, Charterhouse acquired Doc Generici, an Italian pharmaceutical business, selling in 2016 to CVC Capital Partners.[11] In 2013, the company acquired Armacell in a €520 million deal and, in 2015, sold to a Blackstone led partnership in a deal valued at €960 million.[12] In 2015, Charterhouse acquired Mirion Technologies, a radiation detection provider, for $750 million, and in June 2021, Mirion announced it would go public after merging with a Goldman Sachs backed SPAC in a deal valued at $2.6 billion.[13] In 2016, the company acquired Cooper, a provider of generalist over-the-counter (OTC) self-care pharmaceuticals, and in March 2021 sold a majority stake to CVC.[14] In 2017, the company acquired a majority stake in SERB, a Brussels headquartered specialty pharmaceuticals company.[15] In 2018, they acquired a majority stake in Siaci Saint Honore (SSH), a B2B insurance broker, and sold in July 2021 to a consortium led by Burrus Group.[16] In March 2018, the company acquired SLR Consulting, a UK environmental consultancy previously owned by 3i, becoming a major shareholder.[17] In June 2019, Charterhouse disposed of Italian cheese maker and distributor Nuova Castelli, which had been in their possession since 2014, and which was acquired by the Lactalis Group Italia.[18][19] In December 2020, SERB pharmaceuticals, backed by Charterhouse Capital Partners, agreed to purchase Boston Scientific's BTG specialty pharma unit for $800m.[20] In the same month, the company acquired Inflexion Private Equity's minority stake in the UK pension provider Lane Clark & Peacock.[21] Also in December 2020, Charterhouse concluded a deal with French banking group Crédit Mutuel Arkéa, for a stake in the Dutch software company Vermeg.[22] In June 2022, Charterhouse disposed of SLR Consulting to a private equity fund managed by Ares Management.[23][24] In March 2023, in a cash and shares deal, Charterhouse sold the Irish Tarsus Group to Informa for a reported GBP 790m.[25][26][27] In April 2023, the company’s sale of French telecom’s Sagemcom to a continuation fund backed by AlpInvest Partners was officially recorded.[28] In the same month, Charterhouse confirmed their investment in a management buyout of France Valley Investissements, the €4 billion forestry and real assets manager, together with Guillaume Toussaint and Arno Filhol and their management team, to support France Valley’s intended launch of ESG-linked products.[29][30] References
External links
|
||||||||||||||||
